

Applicant : Masayuki Tsuchiya et al.
Serial No. : To Be Assigned
Filed : Herewith
Page : 2 of 4

Attorney's Docket No.: 14875-144US1 / C1-A0230P-US

Amendments to the Specification:

Please replace the original paper copy of the Sequence Listing with the substitute paper copy of the Sequence Listing filed herewith.

At page 1, line 1, please delete subheading:

~~DESCRIPTION~~

Please amend the title to read as:

ANTIBODIES AGAINST LESIONAL TISSUES

Please insert the following paragraph after the title:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is the National Stage of International Application No. PCT/JP2003/014919, filed November 21, 2003, which claims the benefit of Japanese Patent Application No. 2002-339241, filed on November 22, 2002. The contents of both applications are hereby incorporated by reference in their entireties.

Please replace the paragraph beginning at page 7, line 35, with the following amended paragraph:

First, mRNAs are extracted from isolated B cells. cDNAs are synthesized by using the extracted mRNAs as a template to obtain a cDNA library. Commercially available kits are conveniently used for extracting mRNAs and for constructing the cDNA library. In this invention, mRNAs derived from a small number of B cells are used. In practice, mRNAs obtained from only a few cells are extremely small in amount, and have low yields when directly purified. Therefore, mRNAs are usually purified after the addition of carrier RNAs that clearly contain no antibody genes. Alternatively, with a certain amount of RNAs being extracted, the mRNAs of antibody-producing cells themselves can also be efficiently extracted. The addition

Applicant : Masayuki Tsuchiya et al.
Serial No. : To Be Assigned
Filed : Herewith
Page : 3 of 4

Attorney's Docket No.: 14875-144US1 / C1-A0230P-US

of carrier RNAs may not be required for extracting mRNAs from, for example, 10 or more, 30 or more, preferably 50 or more antibody-producing cells.